<DOC>
	<DOCNO>NCT01947569</DOCNO>
	<brief_summary>Phase IB evaluate safety autologous , ex vivo-engineered , co-stimulation impaired dendtritic cell maintain improve functional residual beta cell mass new onset Type I Diabetes Mellitus ( T1DM ) patient . Efficacy measure collect summarized . Phase IIA evaluate safety efficacy 3 randomize treatment group new onset T1DM patient assess antisense DNA-treated co-stimulation-impaired immunoregulatory dendritic cell ( iDC ) safely preserve and/or increase B-cell mass result improvement and/or normalization blood glucose level glycated hemoglobin A1c .</brief_summary>
	<brief_title>Dendritic Cells Type 1 Diabetes Mellitus ( T1DM ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>( open label phase IB safety Phase IIA study ) : 1 . Patients new onset T1DM ( &gt; 18 year age phase IB &gt; 16 ( first 10 subject ) , &gt; 12 year age second 10 subject , &gt; 8 year next 10 subject , finally , &gt; 8 year age remainder phase IIA patient ) within 6 month diabetes mellitus diagnosis . 2 . Evidence decrease Î²cell function measure Cpeptide blood glucose level consistent impair glucose tolerance . 3 . Evidence least one highrisk HLA haplotype . 4 . Evidence least one diabetesrelated autoantibody ( e.g . IA2 , GAD , ZnT8 ) , 5 . Adequate immune competence assess immunoreactivity alloantigens mixed leukocyte culture reactivity viral antigen ( CEF Pool Assay ) vitro . 6 . Normal hematologic , liver kidney function . 7 . Female participant childbearing potential study must agree use effective form birth control study participation . Reliable effective form birth control include : true abstinence , intrauterine device ( IUD ) , hormonalbased contraception , doublebarrier contraception [ condom occlusive cap ( diaphragm cervical cap ) spermicide ] , surgical sterilization ( vasectomy male partner , tubal ligation hysterectomy ) . Sexually active male participant must agree use effective form birth control condom . ( open label phase IB safety Phase IIA study ) : 1 . Enrollment history enrollment drug , biologic therapy study sponsor TrialNet . 2 . A significant history current evidence cardiac disease , uncontrolled hypertension , serious arrhythmia . 3 . Evidence active infection require antibiotic therapy . 4 . History concurrent significant medical disease . 5 . Pregnant lactating woman . 6 . Patients require chronic systemic corticosteroid . 7 . Any immune disorder include limited autoimmune disease , HIV , HBV , HCV , HPV , HSV positivity . 8 . Impaired renal function creatinine level &gt; 1.5 . 9 . Administration follow therapy patient undergo treatment protocol : ) radiation therapy ; ii ) chemotherapy ; iii ) corticosteroid ( except administer lifethreatening circumstance ) ; iv ) particle cellbased therapy ; v ) biologic therapy ; vi ) therapy aim modulate immune system ; vii ) endocrinerelated therapy , hormone replacement ( thyroxine contraceptive ) , glucoregulation . 10 . A hemaglobinopathy know interfere ability accurately determine HbA1c . 11 . No prior radiation therapy , immunotherapy , chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>